No Data
No Data
No Data
No Data
No Data
Express News | Quince Therapeutics Q4 EPS $(0.21) Down From $(0.13) YoY
Moomoo 24/7Apr 2 08:12 ET
Quince Therapeutics Reported $75.1M in Cash as of December 31, 2023, Expect to Fully Fund Lead Asset, EryDex, Through Phase 3 NEAT Topline Results and Prepare for a Potential NDA Submission in 2026
Strong Cash Position Expected to Support Meaningful Clinical MilestoneReported $75.1 million in cash, cash equivalents, and short-term investments as of December 31, 2023. Quince expects its existing
BenzingaApr 1 07:08 ET
Press Release: Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 01, 2024-- Quince Therapeutics, Inc. (Na
Dow JonesApr 1 07:00 ET
Quince Therapeutics Launches Scientific Advisory Board
World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company's lead Phase 3 asset, new indications, and pipeline expansion Quince Therapeutics, Inc.
BusinesswireFeb 22 07:00 ET
Quince Therapeutics Appoints Rajiv Patni to Board of Directors
TipRanksFeb 15 16:14 ET
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to Its Board of Directors
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced
BusinesswireFeb 15 07:00 ET
No Data
No Data